Mycenax Biotech Inc. (TPEX:4726)
23.90
+0.20 (0.84%)
Sep 8, 2026, 1:30 PM CST
Mycenax Biotech Revenue
Mycenax Biotech had revenue of 203.09M TWD in the quarter ending June 30, 2026, with 0.26% growth. This brings the company's revenue in the last twelve months to 815.87M, up 12.16% year-over-year. In the year 2025, Mycenax Biotech had annual revenue of 740.24M with 8.23% growth.
Revenue (ttm)
815.87M
Revenue Growth
+12.16%
P/S Ratio
6.01
Revenue / Employee
2.11M
Employees
387
Market Cap
4.91B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 740.24M | 56.31M | 8.23% |
| Dec 31, 2024 | 683.92M | 31.30M | 4.80% |
| Dec 31, 2023 | 652.62M | -79.66M | -10.88% |
| Dec 31, 2022 | 732.28M | -41.99M | -5.42% |
| Dec 31, 2021 | 774.27M | 108.93M | 16.37% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sinphar Pharmaceutical | 3.45B |
| Medigen Biotechnology | 1.27B |
| Savior Lifetec | 1.12B |
| TaiGen Biopharmaceuticals Holdings | 256.46M |
| BioGend Therapeutics | 236.58M |
| Pharmosa Biopharm | 53.38M |
| Formosa Pharmaceuticals | 52.59M |
| UnicoCell Biomed | 22.46M |